NEOS Investment Management LLC Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

NEOS Investment Management LLC grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 350,036 shares of the biopharmaceutical company's stock after acquiring an additional 84,536 shares during the quarter. NEOS Investment Management LLC's holdings in Pfizer were worth $9,286,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer in the 4th quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.19 during mid-day trading on Friday, reaching $25.20. 32,322,049 shares of the company traded hands, compared to its average volume of 39,037,478. The company's 50 day moving average price is $26.06 and its 200-day moving average price is $26.92. The firm has a market cap of $142.93 billion, a PE ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The company's revenue was up 24.7% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.